

Criteria. The patient must meet the following criteria: IVIG is prescribed by or in consultation with a neurologist.

In several placebo-controlled trials, IVIG improved muscle strength and neurological disability scores.^{5,36-38,47} IVIG is the only proven effective treatment and is considered first-line treatment. Plasma exchange and corticosteroids are not effective. IVIG is beneficial in maintenance treatment but the disease continues to progress over many years.

Dosing in Multifocal Motor Neuropathy (MMN). Dosing must meet ONE of the following (A OR B):

- A)** Therapy is initiated with 2 g per kg IV infusion given in divided doses over 2 to 5 consecutive days;⁴⁷ OR
- B)** ONE of the following maintenance dosing regimen is used (i, ii, or iii):
 - i.** 0.5 to 2.4 g per kg IV infusion every month;⁵ OR
 - ii.** 1 g per kg IV infusion every 2 to 4 weeks;⁴⁷ OR
 - iii.** 2 g per kg IV infusion every 1 to 2 months.⁴⁷

The approved dosage range is 0.5 to 2.4 g per kg per month.⁵ The dose is adjusted to achieve the desired clinical response. In the pivotal trial that established efficacy and safety of IVIG, adults who were receiving maintenance IVIG 0.5 to 2.0 g/kg/month prior to enrollment were included. The results from this trial cannot be generalized to naïve patients. Many regimens have been used for initiating therapy and for maintenance therapy. The European Federation of Neurological Societies (EFNS)/Peripheral Nerve Society Guideline on management of MMN recommends initial therapy with IVIG 2 g/kg given over 2 to 5 days.⁴⁷ Typical maintenance treatment regimens are 1 g/kg every 2 to 4 weeks or 2 g/kg every 4 to 8 weeks. In general the IVIG infusion needs to be repeated frequently, every 4 to 12 weeks.^{36-37,47}

Repeated treatment with IVIG should be considered if the initial infusion of IVIG is effective. In patients who do not improve after Cycle 2 of IVIG treatment, the dose can be increased or decreased and/or the interval can be increased or decreased. In patients who respond, dosing should be aimed at maintaining optimal function. In patients who respond, the interval between doses can be increased to every 4 to 8 weeks, depending on response. Dosing must be individualized and is very variable; increasing the dose vs. increasing the interval may provide differing results and therefore is individualized. Note: alternate dosing will be assessed individually on a case-by-case basis.

Initial Approval/Extended Approval.

- A)** Initial Approval. Approve for 6 months.
- B)** Extended Approval. Approve for an additional 6 months of therapy if the patient has improvement in neurologic symptoms as determined by the prescribing physician (a neurologist or in consultation with a neurologist). IVIG should be discontinued in patients who do not respond after the first 6 months of therapy. Continue approving at 6-month intervals in patients who are responding (that is, maintaining optimal function) according to the prescribing physician.

Duration of Therapy in Multifocal Motor Neuropathy (MMN). Indefinite for patients who are responding, according to the prescribing physician.

It is well accepted that therapy should be continuous in patients who respond. The frequency of the treatment courses will vary and may shorten over time. Despite IVIG therapy, weakness continues to increase.^{37-38,47}

Labs/Diagnostics. None required.

Other Uses with Supportive Evidence

7. Antibody-Mediated Rejection (ABMR) in Solid Organ Transplant (e.g., Kidney, Heart, Lung, Liver).

Criteria. Approve IVIG if prescribed by or in consultation with a physician affiliated with a transplant center.

Current strategies for a treatment of antibody-mediated rejection include plasmapheresis, intravenous immunoglobulin and T-cell or B-cell-depleting agents.¹⁵⁷ Although there are no controlled trials regarding the most appropriate treatments, the benefits of immune globulin have been well described and has been used as the standard-of-care (along with plasmapheresis) in multiple studies.^{18,158} Clinical practice guidelines (2009 Kidney Disease: Improving Global Outcomes [KDIGO]) recommends a combination of corticosteroids, plasmapheresis, IVIG, anti-CD-20 antibody and lymphocyte-depleting antibody for antibody-mediated rejection.^{158,159} As in desensitization therapy with solid organ transplants, much of the information on IVIG use is in patients with kidney transplants, but the same principles apply to transplantation of other organs and tissues. Immune globulin has been used in lung transplant patients to treat ABMR¹⁶⁰⁻¹⁶² and a scientific statement from the AHA states that primary therapy for ABMR in patients with heart transplants may include IVIG, plasmapheresis, high-dose corticosteroids and anti-lymphocyte antibodies.⁶⁸

Dosing for Antibody-Mediated Rejection. Various dosing regimens have been used for this diagnosis and dosing regimens will be evaluated on a case-by-case basis.

Initial Approval/Extended Approval.

Initial and Extended Approval. Approve for 1 year.

Duration of Therapy for Antibody-Mediated Rejection. ABMR can be diagnosed within the first year post-transplant OR after the first year (late-onset or chronic).

Labs/Diagnostics. None required.

8. Autoimmune Mucocutaneous Blistering Diseases (Pemphigus Vulgaris, Pemphigus Foliaceus, Bullous Pemphigoid, Mucous Membrane Pemphigoid [Cicatricial Pemphigoid], and Epidermolysis Bullosa Acquisita).

Criteria. *The patient must meet the following criteria (A AND B):*

PM145_CCC_Immune_Globulin_Intravenous_ (Multiple brand names)

15 of 59



- A) IVIG is prescribed by or in consultation with a dermatologist; AND
- B) The patient meets ONE of the following (i, ii or iii):⁴⁸⁻⁵⁰
 - i. The patient has tried a systemic corticosteroid OR a corticosteroid is contraindicated according to the prescribing physician, AND the patient has tried an immunosuppressive agent (e.g., azathioprine, cyclophosphamide, dapsone, methotrexate [MTX], cyclosporine, mycophenolate mofetil, tacrolimus) OR an immunosuppressive agent is contraindicated according to the prescribing physician; OR
 - ii. The patient has rapid, debilitating, progressive disease, that cannot be controlled with a systemic corticosteroid and an immunosuppressive agent; OR
 - iii. The disease is so serious that there is inadequate time for therapy with a systemic corticosteroid and an immunosuppressive agent to have a rapid enough effect.

Conventional therapy (a systemic corticosteroid and an immunosuppressive agent) is started at the same time or before IVIG. Many case reports and uncontrolled case series suggest benefit of IVIG in patients with recalcitrant disease or in those with contraindications to conventional therapy.^{48,50} The total duration of treatment with IVIG can be at least 2 years or longer.⁴⁸ The interval between infusions is increased gradually and prolonged clinical remission has been reported with pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, and mucous membrane pemphigoid (cicatrical pemphigoid).

Dosing for the Autoimmune Mucocutaneous Blistering Diseases. *Dosing must meet ONE of the following (A, B, OR C):*

- A) 2 g per kg IV infusion per cycle administered every 3 to 4 weeks initially.⁴⁸⁻⁴⁹ This dose is divided over 2, 3, or 5 consecutive days;⁴⁸ OR
- B) In patients with aggressive ocular disease such as ocular cicatricial pemphigoid, 2 g per kg IV infusions may be given every 2 weeks in divided doses over 2, 3, or 5 consecutive days;⁴⁸ OR
- C) The frequency of IVIG is gradually being slowly decreased as the lesions resolve and heal.⁴⁸⁻⁴⁹

When the disease is stable, IVIG is continued about every 4 weeks. Once previous lesions are healed and there have been no new lesions for several weeks, the frequency of IVIG treatments can be slowly decreased with the dose remaining the same. Some patients can be gradually tapered off IVIG.

Initial Approval/Extended Approval.

- A) *Initial Approval.* Approve for 6 months.⁴⁹
- B) *Extended Approval.* Approve for 6 months if the patient has responded (previous lesions are healing and there are fewer new lesions) according to the prescribing physician.

Patients who respond to IVIG may be tapered off corticosteroids and have immunosuppressive therapy discontinued. Then if disease is controlled, may try to taper off IVIG.

Duration of Therapy for Autoimmune Mucocutaneous Blistering Diseases. The total duration of treatment with IVIG can be ≥ 2 years.⁴⁸

Labs/Diagnostics. None required.

9. Cytomegalovirus (CMV) Interstitial Pneumonia in Patients with Hematopoietic Cell Transplantation (HCT).

Criteria. Approve if IVIG is prescribed by or in consultation with an oncologist, hematologist, or an infectious diseases physician.

For CMV pneumonia, therapy consists of ganciclovir IV injection (or foscarnet IV injection if CMV is ganciclovir-resistant) and IVIG in combination.⁵¹ Whether adding IVIG adds efficacy is controversial,^{52,54} and there are no data to support adding IVIG for the treatment of any manifestation of CMV disease other than pneumonia.⁵² Cytogam® (CMV immune globulin IV injection) may be preferred instead of IVIG for interstitial pneumonia. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT) recommends the combination of ganciclovir and IVIG for the therapy of CMV pneumonia.⁵² For other types of CMV disease, the EBMT recommends ganciclovir or foscarnet without IVIG. These recommendations are consistent with the NCCN guidelines on prevention and treatment of cancer-related infections (version 2.2017) that say IVIG may be added to ganciclovir or foscarnet for treatment of CMV pneumonia.⁵¹ IVIG is not indicated for CMV prophylaxis and preemptive therapy. (See Conditions Not Recommended for Approval.)

Dosing in CMV Interstitial Pneumonia. Dosing must meet the following: 400 mg per kg IV infusion every other day for 3 to 5 doses.⁵¹

Dosing recommended in the NCCN guidelines is 400 mg/kg every other day for three to five doses.⁵¹ The optimal dosing schedule has not been defined.

Initial Approval/Extended Approval.

- A) Initial Approval. Approve for 2 months.
- B) Extended Approval. Not recommended.

IVIG is given with ganciclovir (or foscarnet) which is given for 4 to 6 weeks.⁵¹

Duration of Therapy in CMV Interstitial Pneumonia. The duration of therapy is a maximum of 2 months.

Labs/Diagnostics. None required.

10. Dermatomyositis or Polymyositis.

Criteria. The patient must meet the following criteria (A, B, AND C):

- A) IVIG is prescribed by or in consultation with a neurologist or a rheumatologist; AND
- B) The patient has tried a systemic corticosteroid^{36,38,55-56} OR a corticosteroid is contraindicated according to the prescribing physician; AND
- C) The patient has tried an immunosuppressive agent (e.g., azathioprine, MTX, cyclosporine, cyclophosphamide, mycophenolate mofetil)^{36,55-56} OR an immunosuppressive agent is contraindicated according to the prescribing physician.

IVIG may be used in patients with dermatomyositis with severe active illness for whom other interventions have been unsuccessful or intolerable.⁵⁵⁻⁵⁶ In one double-blind, placebo-controlled crossover trial, patients with treatment resistant dermatomyositis who received IVIG for 3 months had significant improvement in muscle strength, neuromuscular symptoms, and rash.⁵⁷ IVIG has been used to maintain response in dermatomyositis.

IVIG may be considered among the treatment options for patients with polymyositis not responding to first-line immunosuppressive treatment.^{38,55} In uncontrolled series, IVIG has been effective in polymyositis.

Dosing in Dermatomyositis or Polymyositis. *Dosing must meet ONE of the following (A OR B):*

- A) 2 g per kg IV infusion given in divided doses over 2 to 5 consecutive days once monthly;^{36,38,57} OR
- B) 2 g per kg IV infusion given in divided doses over 2 to 5 consecutive days every 2 to 3 weeks.³⁸

Initial Approval/Extended Approval.

- A) *Initial Approval.* Approve for 3 months of therapy.^{38,57}
- B) *Extended Approval.* Approve at 6-month intervals if the patient has responded (such as improved muscle strength, improved neuromuscular symptoms, improved functional ability) according to the prescribing physician.

Duration of Approval in Dermatomyositis or Polymyositis. Indefinite in patients who are responding.⁵⁶

Labs/Diagnostics. None required.

11. Desensitization Therapy Prior to and Immediately after Solid Organ (Kidney, Heart, Lung, Liver, Intestinal) Transplantation.

Criteria. Approve IVIG if prescribed by or in consultation with a physician affiliated with a transplant center.

Patients with preexisting anti-human leukocyte antigen (HLA) antibodies (sensitized patients) are more likely to have a positive cross match with possible donors and have a lower likelihood of receiving a solid organ transplant with longer wait times. Most of the information on use of IVIG for desensitization is in patients with kidney transplantation but many of the same principles apply to transplantation of other organs and tissues.⁵⁸⁻⁵⁹ Current protocols include using low-dose IVIG with plasma exchange or high-dose IVIG with or without B-cell depletions with Rituxan[®] (rituximab injection for IV infusion).¹⁸

Kidney. IVIG has been used in highly sensitized patients to reduce allosensitization, ischemia-reperfusion injuries, and acute antibody-mediated rejection (ABMR) episodes in renal allograft recipients.^{18,58,60-63} IVIG has been used alone or after plasmapheresis. IVIG is also used in combination with Rituxan.[®] In one Phase III double-blind trial in patients with end stage renal disease (ESRD), IVIG was better than placebo in reducing anti-HLA antibody levels and improving transplantation rates in highly sensitized patients.⁶⁰

Heart. IVIG has been used as a desensitization agent in patients undergoing cardiac transplantation.⁶²⁻⁶³ Randomized trials are not available and many of the studies have not defined response. The studies have not shown that IVIG alone reduced antibody and results concerning survival after transplant are conflicting. In one study in sensitized patients with a left ventricular assist device who were awaiting cardiac transplant, treatment with IVIG reduced serum reactivity to HLA class I antigens, decreased the risk of positive cross-match reactions, and shortened the waiting time for cardiac transplantation.⁶⁴ In another study, in 35 sensitized patients who had orthotopic heart transplantation, IVIG was used with plasmapheresis pre-transplant to allow successful cardiac transplantation and to improve survival.⁶⁵

Lung or Liver. The role of IVIG or any other desensitization therapy in patients prior to *lung* transplantation who are sensitized to HLA is not known.⁶² There is insufficient evidence to recommend for or against use of IVIG in these patients for desensitization or for treatment of rejection.⁶²⁻⁶³ Regarding *liver* transplantation, ABMR after transplantation is rare and patients are not routinely evaluated for HLA antibody formation.⁶² According to guidelines from the Canadian Blood Services and the National Advisory Committee on Blood and Blood Products of Canada⁶² there is insufficient evidence to make a recommendation for or against routine use of IVIG in preparation for liver transplantation or for treatment of rejection/ABO-incompatible liver transplantation. Use of IVIG in combination with other therapies in patients undergoing lung or liver transplantation requires further study.

Small intestine. Limited published information is available in sensitized recipients of small intestine transplants.⁶⁶⁻⁶⁷ In a pilot study, highly sensitized patients (n = 6) with intestinal failure (short gut syndrome) who were awaiting isolated small bowel transplant received IVIG and immunosuppressive therapy pre-transplant.⁶⁶ Four of the six patients had reduction in high panel peak reactive antibody (PRA) and received intestinal transplantation. Patients continued on IVIG post-transplant at Days 1, 7 and 21. The waiting time for transplant and mortality was similar to non-sensitized patients.

IVIG is also used post-transplant to treat acute ABMR and steroid-resistant acute cellular rejection.^{18,62} Published data are sparse. These patients are hospitalized. A scientific statement from the AHA states that primary therapy for ABMR in patients with heart transplants may include IVIG, plasmapheresis, high-dose corticosteroids, and anti-lymphocyte antibodies.⁶⁸

Dosing for Desensitization Therapy Prior to and Immediately after Solid Organ (Kidney, Heart, Lung, Liver, Intestinal) Transplantation. Dosing must meet ONE of the following (A OR B):

- A)** 2 g per kg as an IV infusion (as a single dose or divided in smaller doses [e.g., 400 mg per kg daily for 5 days]) monthly,⁵⁹⁻⁶¹ OR
- B)** The IVIG dosage is based on a transplant center's protocol.⁵⁸

In one Phase III trial in adults with ESRD, 2 g of IVIG/kg (maximum dose 180 g) was given monthly for 4 months.⁶⁰ Additional infusions of IVIG were given at 12 and 24 months after entering the study in patients who had not received a transplant. In patients who were transplanted, additional 2g/kg infusions of IVIG were given monthly for 4 months. In one guideline, a single IVIG dose of 2 g/kg is recommended in the first week after transplantation.⁶² Low dose IVIG (e.g., 100 mg/kg) has been used with plasmapheresis.^{59,62-63}

Initial Approval/Extended Approval.

- A) *Initial Approval.* Approve for 4 months of therapy.
- B) *Extended Approval.* Approve at 4-month intervals before transplantation OR for one time post-transplantation.

Duration of Approval for Desensitization Therapy Prior to and Immediately after Solid Organ Transplantation. Indefinite in patients who are awaiting transplantation.

Labs/Diagnostics. None required.

12. Guillain Barrè Syndrome (GBS).

Criteria. *The patient must meet the following criteria (A AND B):*

- A) IVIG is prescribed by or in consultation with a neurologist or a specialist with experience in diagnosing and treating patients with GBS; AND
- B) The patient meets one of the following criteria (i or ii):
 - i. IVIG is initiated within 2 weeks and no longer than 4 weeks of onset of neuropathic symptoms (weakness, inability to stand or walk without assistance, respiratory or bulbar weakness); OR
 - ii. The patient has had a relapse (treatment related fluctuation), but had an initial response to IVIG.

IVIG is recommended as an equivalent alternative to plasma exchange in children and adults with GBS.^{34,36,69} IVIG is the treatment of choice, since plasmapheresis is not always readily available.⁷⁰ In controlled trials, IVIG was as effective or more effective than plasmapheresis in improving strength, time to unaided walking, or discontinuation of ventilation.³⁶ The effects of IVIG and plasma exchange are equivalent in hastening recovery, and multiple complications are less frequent with IVIG than with plasma exchange.⁶⁹ The American Academy of Neurology (AAN) recommends IVIG in patients who require aid to walk within 2 or 4 weeks from the onset of neuropathic symptoms.⁷⁰ Treatment with IVIG after 4 weeks from onset is indicated since some patients may deteriorate after initial improvement and the relapse may be severe enough to warrant a repeat course of IVIG.³⁶⁻³⁷ The first course of IVIG therapy may have been given in a hospital.

Patients who receive IVIG for GBS are usually hospitalized. Patients with severe GBS, that is, patients with bulbar or respiratory weakness, muscle weakness, inability to stand or walk and whose symptoms are progressing over 7 to 10 days or who have symptoms that interfere with eating or breathing are hospitalized for treatment with IVIG or plasma exchange. In children symptoms are different and usually are leg or back pain and with progression being more rapid than in adults.³⁴ Many patients with GBS recover fully without therapy. The effect of IVIG in GBS has only been investigated in randomized controlled trials in patients who are unable to walk at nadir (i.e., severely affected patients), not in mildly affected patients who are able to walk unaided at nadir.⁷¹ IVIG is not indicated or proven to be effective in mildly affected GBS patients.^{55,71}

The EFNS task force on the use of IVIG in the treatment of neurological diseases states that no recommendation can be made as to whether patients with Miller Fisher syndrome (a variant of GBS) should be treated with IVIG, because this has not been well-studied.⁵⁵ In a retrospective review of 92 patients with Miller Fisher syndrome, the authors concluded that IVIG and plasmapheresis did not seem to have influenced patients' outcomes. The American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) consensus statement on the use of IVIG in neuromuscular conditions notes, on the basis of a single retrospective analysis and case reports, it is difficult to clearly define the role of IVIG in treating Miller Fischer syndrome.³⁸ Further, the literature suggests that best medical management may suffice for many patients.

Dosing for Guillain Barré Syndrome (GBS). *Dosing must meet the following:* 2 g per kg IV infusion in divided doses over 2 to 5 days.^{34,36,38,55,71}

This is one course and the first course may have been given in a hospital.

Initial Approval/Extended Approval.

- A) *Initial Approval.* Approve one course of treatment (2 g/kg in divided doses over 2 to 5 days).
- B) *Extended Approval.* A second course of treatment may be given about 3 weeks after the first course.

Duration of Therapy for Guillain Barré Syndrome (GBS). Two courses of therapy maximum.

Note: The first course may have been given in a hospital.

Labs/Diagnostics. None required.

13. Hematologic Neoplasm-Associated Hypogammaglobulinemia (Secondary Immunodeficiency [SID]).

(See B-Cell Chronic Lymphocytic Leukemia [CLL] for Prevention of Bacterial Infections and Multiple Myeloma for these diagnosis-specific criteria)

Criteria. *The patient must meet the following criteria (A, B, AND C):*

- A) The patient has an immunoglobulin G (IgG) level of < 500 mg/dL (excluding paraprotein);¹⁶³ AND
- B) The patient has recurrent or severe bacterial infections¹⁶³ or there is a high risk of infection, according to the prescribing physician; AND
- C) IVIG is being prescribed by or in consultation with an oncologist, hematologist, or infectious diseases physician.

Dosing for Hematologic Neoplasm-Associated Hypogammaglobulinemia. Various dosing regimens have been used for this diagnosis. Typical dosing is 400-500 mg/kg monthly.^{163, 164}

Initial Approval/Extended Approval.

- A) *Initial Approval.* Approve for 6 months.

- B) Extended Approval.** Approve for additional 6 months if the patient is maintaining an IgG level of over 400 mg/dL and having a positive response to therapy (e.g., decrease in infections), according to the prescribing physician.

Duration of Therapy in Hematologic Neoplasm-Associated Hypogammaglobulinemia. There is no consensus on duration of therapy. IgG levels and resolution of infections should be monitored to guide duration of therapy.¹⁶⁴

Labs/Diagnostics. IgG level is required as part of the diagnosis.

14. Hematopoietic Cell Transplantation (HCT) to Prevent Bacterial Infection.

Criteria. *The patient must meet the following criteria (A, B, C, AND D):*

- A)** IVIG is prescribed by or in consultation with a oncologist, hematologist, or infectious diseases physician; AND
- B)** The patient has had a HCT within the previous year: AND
- C)** The patient has an immunoglobulin G (IgG) level < 500 mg/dL OR the patient has multiple myeloma or malignant macroglobulinemia (In the professional opinion of a specialist physician, we have adopted this criterion for immunoglobulin G (IgG) level < 500 mg/dL); AND
- D)** According to the prescribing physician the patient has a significant risk of having frequent and/or severe bacterial infections despite antibiotic therapy.

HCT is defined as transplantation of any blood- or marrow-derived hematopoietic stem cells, regardless of transplant type (i.e., allogeneic or autologous) or cell source (i.e., bone marrow, peripheral blood, or umbilical cord blood).⁷² With regard to IVIG, guidelines recommend the following for prevention or preemptive treatment of specific infections in HCT recipients.⁷² In adult or adolescent HCT recipients (allogeneic or autologous), IVIG is indicated to prevent bacterial infections in those with severe hypogammaglobulinemia (i.e., serum IgG < 400 mg/dL) during the first 100 days after HCT. In pediatric patients, IVIG is indicated in those with an *allogeneic* HCT if hypogammaglobulinemia is severe during the first 100 days after HCT. For prevention of bacterial infections beyond 100 days post-HCT (allogeneic or autologous), IVIG is recommended in recipients with severe hypogammaglobulinemia (i.e., serum IgG < 400 mg/dL).

Although IVIG has been recommended for use in producing immune system modulation for the prevention of graft-versus-host disease (GVHD), routine administration of IVIG to HCT recipients for prophylaxis of bacterial infection within the first 100 days after transplantation is not recommended.⁷² Some centers check total IgG levels in high-risk HCT recipients (e.g., those with unrelated marrow grafts). For patients with severe hypogammaglobulinemia (i.e., IgG < 400 mg/dL) IVIG prophylaxis may be considered to maintain a trough serum IgG concentration > 400 mg/dL. Also, in preventing late disease (> 100 days after HCT), routine use of IVIG monthly is not recommended unless the IgG level is < 400 mg/dL to prevent bacterial infections. These reduced levels may be associated with bacteremia or recurrent sinopulmonary infections.

In a randomized trial where IVIG or no IVIG prophylaxis were given from Day 90 to Day 360 post-bone marrow transplant (with patients receiving MTX plus cyclosporine for GVHD prophylaxis), the incidence of bacteremia, sepsis, localized infection, survival, obliterative bronchiolitis, or the incidence or mortality of chronic GVHD were not reduced with IVIG.⁷³ Patients with severe demonstrable hypogammaglobulinemia (e.g., IgG levels < 400 mg/dL) can continue receiving IVIG.⁷²⁻⁷⁴ IVIG supplementation is often used in patients with severe infections and IgG levels < 400 mg/dL to maintain levels until infections resolve.⁷⁴

Gamimune® N, a brand of IVIG that has been discontinued, was FDA-approved for the treatment of bone marrow transplant in patients ≥ 20 years of age to decrease the risk of septicemia and other infections, interstitial pneumonia of infectious or idiopathic etiologies, and acute GVHD in the first 100 days post-transplant.⁷⁵ Currently marketed IVIG products do not carry this indication.

Dosing in Hematopoietic Cell Transplantation (HCT). *Dosing must meet ONE of the following (A OR B):*

- A) During the first 100 days after HCT, the patient meets ONE of the following (i or ii):
 - i. Adults and adolescents: 0.5 g per kg per week as an IV infusion and the dose is adjusted to maintain trough (pre-dose) serum IgG greater than 400 to 500 mg per dL;⁷² OR
 - ii. Pediatric patient with allogeneic HCT: 0.4 g per kg per month as an IV infusion and the dose is adjusted to keep IgG greater than 400 mg/dL;⁷²
- B) Greater than 100 days post-HCT, the dose is 0.5 g per kg IV infusion every 3 to 4 weeks, and the dose is adjusted to keep IgG greater than 400 mg/dL.⁷²

Guidelines from the American Society for Blood and Marrow Transplantation (ASBMT) recommend the following dosing in HCT recipients to prevent infectious complication.⁷² During the first 100 days after HCT, the dose in adults and adolescents is 0.5 g/kg per week. The IVIG dose should be individualized to maintain trough (pre-dose) serum IgG greater than 400 to 500 mg/dL. The dose in allogeneic pediatric HCT patients is 0.4 g/kg per month, adjusted to keep IgG > 400 mg/dL. Higher and more frequent dosing may be necessary in patients for prevention of early disease after HCT because the half-life of IVIG is reduced to 1 to 10 days in this population. Dosing for > 100 days post-HCT is 0.5 g/kg every 3 to 4 weeks. The dose is not adjusted using serum IgG level in patients with multiple myeloma or malignant macroglobulinemia.

Initial Approval/Extended Approval.

- A) *Initial Approval.* Approve for 3 months.
- B) *Extended Approval.* Approve at 3-month intervals if the patient requires IVIG to maintain trough IgG levels > 400 to 500 mg/dL AND who according to the prescribing physician have significant risk of having frequent and/or severe bacterial infections despite antibiotic therapy.

Note: Most patients who receive IVIG require a maximum of 6 doses.

Duration of Therapy in Hematopoietic Cell Transplantation (HCT). Up to 12 months.

Generally IVIG is given for 6 months in patients with hypogammaglobulinemia and who have significant risk of frequent and/or severe bacterial infections despite antibiotic therapy. Some patients with recurrent infections may require therapy for one year and rarely longer.

Labs/Diagnostics. IgG level at baseline (< 500 mg/dL) and IgG trough (pre-dose) level every 2 weeks.⁷²

15. Human Immunodeficiency Virus (HIV)-Associated Thrombocytopenia.

Criteria. *The patient must meet the following criteria (A AND B):*

- A)** IVIG is prescribed by or in consultation with an infectious diseases specialist⁴¹ or a physician who specializes in the treatment of HIV infection; AND
- B)** The patient meets one of the following criteria (i or ii):
 - i.** The patient is receiving combination antiretroviral therapy (cART) for their HIV infection;
OR
 - ii.** The patient has clinically significant bleeding complications⁴¹ according to the prescribing physician.

Secondary ITP can occur in patients with HIV infection.⁴¹ Effective viral suppression using antiretroviral therapy improves HIV-associated cytopenias, including thrombocytopenia. Treatment of secondary ITP (HIV-associated) with short-term corticosteroid therapy increases the platelet count in a similar manner as in non-HIV infected persons and does not appear to be associated with adverse effects. IVIG and Rh₀(D) immune globulin (IV or intramuscular [IM] injection) [Rhophylac[®]/WinRho[®] SDF] have been reported to increase the platelet count. Splenectomy is an effective option for patients who fail to respond to corticosteroid or IVIG therapy.

Evidence for IVIG use in HIV-associated thrombocytopenia is mostly based on case reports and cohort studies and most studies predate the current standard practices for treatment of HIV.⁷⁶⁻⁷⁷ Rh₀(D) immune globulin is FDA-approved in non-splenectomized, Rh₀(D) positive patients for the treatment of childhood acute or chronic ITP, chronic ITP in adults, and ITP secondary to HIV infection (adults and children).⁷⁸ The safety and efficacy of Rh₀(D) immune globulin have not been evaluated in patients who are splenectomized or in patients who are Rh₀(D) negative. The American Society of Hematology (ASH) guidelines for immune thrombocytopenia recommend initial treatment with corticosteroids, IVIG, or Rh₀(D) immune globulin for patients with secondary ITP due to HIV (no preference for initial therapy is expressed).⁴¹ In symptomatic patients who fail one of these therapies, splenectomy is recommended. No platelet count cut-offs are addressed in this patient population. A Canadian expert panel of hematologists recommends IVIG as a treatment option when platelet counts are < 10,000/mm³ or when there is active bleeding.³³ Their recommendations do not discuss use of Rh₀(D) immune globulin.

Dosing in Human Immunodeficiency Virus (HIV)-Associated Thrombocytopenia. *Dosing must meet ONE of the following (A OR B):*

- A)** 2 g per kg given as an IV infusion in divided doses over 2 to 5 days;^{33,77} OR
- B)** 1 g per kg one time as an IV infusion for platelet counts less than 20,000 to 30,000 per mm³ and this dose is repeated once weekly if needed.⁷⁶

Very limited information is available on dosing because this condition is not common and most studies predate the most current standard of practice for treatment of HIV infection.

Initial Approval/Extended Approval.

- A) *Initial Approval*. Approve for one month.
- B) *Extended Approval*. Not recommended.

Duration of Therapy in Human Immunodeficiency Virus (HIV)-Associated Thrombocytopenia. One month.

Labs/Diagnostics. None required.

16. Human Immunodeficiency Virus (HIV)-Infected Infants and Children to Prevent Recurrent Bacterial Infections.

Criteria. *The patient must meet the following criteria (A, B, C, AND D):*

- A) IVIG is prescribed by or in consultation with an infectious diseases specialist or an immunologist; AND
- B) The patient is < 18 years of age; AND
- C) The patient is receiving combination antiretroviral therapy (cART); AND
- D) The patient has ONE of the following (i, ii or iii):
 - i. Hypogammaglobulinemia (i.e., IgG < 400 mg/dL);⁷⁹ OR
 - ii. Functional antibody deficiency is demonstrated by poor specific antibody titers (that is, the patient does not develop specific antibody responses against protein and polysaccharide antigens); OR
 - iii. Functional antibody deficiency is demonstrated by the patient having recurrent (two or more per year) serious bacterial infections (e.g., bacteremia, meningitis, pneumonia) despite administration of cART and appropriate antimicrobial prophylaxis.^{79,81}

IVIG is no longer recommended for primary prevention of serious bacterial infections in HIV-infected children unless hypogammaglobulinemia is present or functional antibody deficiency is demonstrated by recurrent bacterial infections.⁷⁹ Usually neither IVIG nor antimicrobial prophylaxis is necessary in patients receiving effective antiretroviral therapy.⁸⁰ In rare situations where cART and antibiotic prophylaxis are not effective in preventing frequent recurrent serious bacterial infections, secondary prophylaxis with IVIG can be considered.⁷⁹ In children with greater than two serious bacterial infections in a 1-year period and who cannot tolerate cART, secondary prophylaxis is indicated. The first choice of therapy for secondary prophylaxis is trimethoprim-sulfamethoxazole and IVIG every 2 to 4 weeks is an alternative.

Gamimune N, a brand of IVIG that has been discontinued, was FDA-approved for pediatric HIV infection to decrease the frequency of serious and minor bacterial infections and the frequency of hospitalization and to increase the time free of serious bacterial infection.^{75,82} Currently marketed IVIG products do not carry this indication.

Clinicians providing care for adolescents are advised to use the U.S. Department of Health and Human Services Adult and Adolescent HIV-guideline for the care of post-pubertal adolescents (sexual

maturity rating [SMR] IV and V) and to use the Pediatric guideline for guidance on the care of adolescents at SMR III or lower.⁷⁹

Dosing in Human Immunodeficiency Virus (HIV)-Infected Infants and Children to Prevent Recurrent Bacterial Infections. *Dosing must meet the following:* IVIG 0.4 g per kg IV infusion every 2 to 4 weeks and the dose and interval between infusions are adjusted according to clinical effectiveness.^{79,82}

The dose of IVIG may be increased to improve clinical effectiveness (frequency or severity of infections, hospitalization, days of school or work missed, failure to thrive).

Initial Approval/Extended Approval.

- A) *Initial Approval.* Approve for up to 6 months.
- B) *Extended Approval.* Continue to approve at 6-month intervals if the frequency and severity of infections has decreased according to the prescribing physician.

Duration of Therapy for Prevention of Recurrent Bacterial Infections. Continue as long as frequent, serious, recurrent bacterial infections cannot be controlled with antibiotic therapy.

Patients with frequent, serious, recurrent bacterial infections that cannot be controlled with antibiotic therapy can continue with IVIG. The duration of therapy will be determined by efficacy and should continue as long as it is working. Children who are stabilized on cART and improve on IG therapy can safely stop IG once T cells have been reconstituted with cART.¹⁸

Labs/Diagnostics. See Criteria 14 D) above: IgG level or testing for antibody response to protein and polysaccharide antigens before starting therapy.

17. Immunotherapy-Related Toxicities Associated with Checkpoint Inhibitor Therapy.

Note: Examples of checkpoint inhibitors are: Keytruda (pembrolizumab), Opdivo (nivolumab), Yervoy (ipilimumab), Tecentriq (atezolizumab), Bavencio (avelumab), Imfinzi (durvalumab).

Criteria. *The patient must meet the following criteria (A or B):*

- A) The patient has tried a systemic corticosteroid (e.g., prednisone, methylprednisolone) and has not adequately responded to therapy, according to the prescribing physician; OR
- B) A corticosteroid is contraindicated, per the prescribing physician.

NCCN has guidelines in partnership with the American Society of Clinical Oncology (ASCO) [version 1.2018- February 14,2018] for Management of Immunotherapy-Related Toxicities (Immune Checkpoint Inhibitor-Related Toxicities).¹⁵⁵ The guidelines recommend considering IVIG in the following circumstances: for the management of severe pneumonitis after 48 hours of methylprednisolone therapy; as treatment for severe myasthenia gravis with no improvement/worsening on high-dose corticosteroids or for severe symptoms; for moderate or severe Guillain-Barre Syndrome or severe peripheral neuropathy in combination with pulse-dose methylprednisolone; as treatment for encephalitis in combination with pulse-dose

methylprednisolone; and severe transverse myelitis. ASCO has also issued practice guidelines on the management of immune-related adverse events in patients treated with checkpoint inhibitor therapy.¹⁵⁶ These practice guidelines address the above mentioned indications along with other diagnoses (e.g., severe cutaneous skin adverse reactions, myositis, autoimmune hemolytic anemia, immune thrombocytopenia).

Dosing for Immunotherapy-Related Toxicities Associated with Checkpoint Inhibitor Therapy. Dosing varies per toxicity; typical dosing regimens are 0.4 g/kg/day for 5 days or 2 g/kg over 2-5 days.¹⁵⁵

Initial Approval/Extended Approval.

- A) *Initial Approval.* Approve for 1 month.
- B) *Extended Approval.* Approve at 6-month intervals if the patient is having a positive response to therapy, as determined by the prescribing physician, and the physician has determined extended therapy is required.

Duration of Therapy for Immunotherapy-Related Toxicities Associated with Checkpoint Inhibitor Therapy. Most IVIG use is short-term for severe (grade 3 or 4) toxicities.

Labs/Diagnostics. None required.

18. Lambert-Eaton Myasthenic Syndrome (LEMS), Treatment.

Criteria. *The patient must meet the following criteria (A AND B):*

- A) IVIG is prescribed by or in consultation with a neurologist; AND
- B) The patient meets ONE of the following conditions (i or ii):
 - i. The patient has paraneoplastic LEMS; OR
 - ii. The patient has non-paraneoplastic LEMS AND meets ONE of the following criteria (a or b):
 - a) The patient has tried at least one of the following: a systemic corticosteroid OR azathioprine OR another immunosuppressive agent (e.g., cyclosporine, mycophenolate mofetil); OR
 - b) The patient has a contraindication to BOTH a corticosteroid AND azathioprine and other immunosuppressive agents³⁶ according to the prescribing physician.

In one placebo-controlled crossover trial, a single dose of IVIG produced significant improvement in muscle strength and reduced serum calcium channel antibody titers in patients with LEMS.⁸³ There have been only five randomized controlled trials of treatment for LEMS: four with 3,4-diaminopyridine (amifampridine tablets) [available in the US through an expanded access use program]⁸⁴ and one with IVIG. Plasma exchange, steroids, and immunosuppressive agents have not been studied in randomized controlled trials. IVIG may be useful as adjunctive therapy in difficult to treat patients.³⁶ IVIG may be used as an alternative in patients who do not respond or do not tolerate other therapies for LEMS.¹⁸

Dosing for Lambert-Eaton Myasthenic Syndrome (LEMS). *Dosing must meet ONE of the following (A OR B):*

- A) 2 g per kg given as an IV infusion in divided doses over 2 to 5 consecutive days;³⁶ OR
- B) Maintenance therapy every 4 weeks with IVIG \leq 2 g per kg with the dose being adjusted based on clinical symptoms.³⁶

Initial Approval/Extended Approval.

- A) *Initial Approval.* Approve for one month.
- B) *Extended Approval.* Approve at 6-month intervals if the patient has a response (e.g., improved muscle strength, other clinical response) or continued effectiveness, according to the prescribing physician.

Duration of Therapy for Lambert-Eaton Myasthenic Syndrome (LEMS). IVIG therapy may continue as long as there is continuing objective clinical improvement or maintenance of improvement as determined by the prescribing physician.

Labs/Diagnostics. None required.

19. Multiple Myeloma.

Criteria. *The patient must meet the following criteria (A, B, AND C):*

- A) The patient has stable (plateau phase) disease (> 3 months from diagnosis); AND
- B) The patient has severe recurrent bacterial infections according to the prescribing physician; AND
- C) IVIG is prescribed by or in consultation with an oncologist, hematologist, or infectious diseases specialist.

Patients with multiple myeloma are often functionally hypogammaglobulinemic with total immunoglobulin production being elevated but the repertoire of antibody production restricted.⁵¹ The NCCN clinical practice guidelines on multiple myeloma (version 3.2017) recommend that IVIG prophylaxis be considered in the setting of recurrent, life-threatening infections.⁸⁵ Prophylactic IVIG replacement therapy has reduced infection rates in patients in the plateau phase, but no effect has been demonstrated in newly diagnosed patients.⁸⁶ In one randomized placebo-controlled trial, prophylactic use of IVIG reduced serious and life-threatening infections in immunosuppressed patients with multiple myeloma.³³ According to a Canadian expert panel of hematologists, IVIG is recommended for infection prophylaxis in these adults who have either a recent episode of a life-threatening infection thought to be caused by low levels of polyclonal immunoglobulins or recurrent episodes of clinically significant infections (e.g., pneumonia) that are caused by low levels of polyclonal immunoglobulins.³³ IVIG is an option for acute life-threatening infections in these patients. This panel of hematologists recommended re-evaluation every 4 to 6 months when used for prophylaxis but there was no consensus on specific criteria to use for duration of treatment with IVIG. In another guideline from the British Committee for Standards in Haematology and UK Myeloma Forum, therapy for up to 6 months was recommended.⁸⁶

Dosing in Multiple Myeloma. *Dosing must meet the following:* 0.4 to 0.5 g per kg as an IV infusion every 3 to 4 weeks.^{33,86}

Initial Approval/Extended Approval.

- A) Initial Approval. Approve for 6 months.⁸⁶
- B) Extended Approval. Approve for additional 6 months.

Duration of Therapy in Multiple Myeloma. 12 months.³³

There is no consensus on duration of therapy.³³

Labs/Diagnostics. None required.

20. Multiple Sclerosis (MS), Acute Severe Exacerbation.

Criteria. The patient must meet the following criteria (A AND B):

- A) IVIG is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of MS; AND
- B) The patient meets one of the following criteria (i or ii):
 - i. The patient has either not responded to OR has had a significant adverse reaction AND is continuing to deteriorate despite therapy with one of the following (a, b, or c):
 - a) Oral or IV corticosteroids (e.g., methylprednisolone sodium succinate); OR
 - b) Plasma exchange; OR
 - c) Acthar® H.P. gel (Acthar) [repository corticotropin injection; adrenocorticotrophic hormone {ACTH}];
 - OR
 - ii. A systemic corticosteroid or Acthar is contraindicated AND the patient is not a candidate for plasma exchange according to the prescribing physician. (In the professional opinion of a specialist physician, we have adopted this criterion.)

High dose corticosteroids, usually methylprednisolone, are first-line treatment of MS relapses in patients with acute optic neuritis, if needed.⁸⁷ Acthar is an option in patients with poor venous access or who prefer to self-inject medication. Second-line therapy with plasmapheresis (plasma exchange) is recommended for steroid-resistant exacerbations in relapsing forms of MS.^{69,87} Two studies showed that IVIG had no effect on recovery from acute relapse when given either concomitantly with, or immediately before therapy with IV methylprednisolone.^{36,55} According to an expert panel of neurologists guidelines, IVIG is only recommended for acute exacerbations of MS in patients with severe refractory optic neuritis who have had no recovery of vision after 3 months of standard steroid therapy or in patients who have a contraindication to corticosteroid therapy.³⁶ For other MS uses (relapsing remitting MS [RRMS]), this panel has recommended either a single 1 g/kg dose or 0.4 g/kg daily for 5 days.

Dosing for Acute Exacerbation of Multiple Sclerosis (MS). Dosing must meet ONE of the following (A OR B):

- A) A single 1 g per kg dose as an IV infusion; OR
- B) 0.4 g per kg per day IV infusion for 5 consecutive days.

Initial Approval/Extended Approval.

- A) Initial Approval. Approve for one course of therapy as listed in dosing.
- B) Extended Approval. Not recommended.

Duration of Therapy in Multiple Sclerosis (MS). One course.

Labs/Diagnostics. None required.

21. Multiple Sclerosis (MS), Post-Partum to Prevent Relapses.

Criteria. The patient must meet the following criteria (A AND B):

- A) IVIG is prescribed by or in consultation with, a neurologist or a physician who specializes in the treatment of MS; AND
- B) The patient is not currently receiving disease modifying therapy (DMT) for MS (e.g., Avonex® [interferon beta-1a injection, IM], Plegridy™ [peginterferon beta-1a SC injection], Rebif® [interferon beta-1a injection, SC], Betaseron®/Extavia® [interferon beta-1b injection], Copaxone®/Glatopa™ [glatiramer acetate injection, SC], Gilenya® [fingolimod capsules], Lemtrada™ [alemtuzumab injection for IV use], Aubagio® [teriflunomide tablets], Tecfidera® [dimethyl fumarate capsules], Tysabri® [natalizumab IV injection], Novantrone® [mitoxantrone injection]) to prevent relapses.

None of the DMTs have been approved for use in women who are nursing. IVIG is the treatment of choice for post-partum mothers with MS who are nursing.⁸⁸

There is an increase in relapse rates in women with MS during the initial 3 months after birth which may continue for up to 6 months (in patients not receiving therapy).⁸⁹⁻⁹¹ In one randomized, confirmatory, multicenter, double-blinded-placebo-period (Days 1 through 3 post-partum) trial, women with clinically confirmed RRMS and at least one relapse within the 2 years prior to pregnancy received treatment with one of the following IVIG regimens: IVIG 150 mg/kg Day 1 post-partum followed by placebo injections on Days 2 and 3 (Group I) or IVIG 900 mg/kg over a 3-day period (Group II).⁹¹ Initial IVIG treatment was followed by an open phase in which both groups received five doses of IVIG 150 mg/kg at monthly (every 4 weeks) intervals. Prior to pregnancy the number of relapses per women per year in the 2 years prior to pregnancy was 1.0 ± 0.7 and 1.0 ± 0.6 in Group I and Group II, respectively. In Groups I and II, 75.6% and 81.5% of patients respectively, remained relapse-free during the 3-month post-partum period (primary efficacy endpoint). The difference between the groups (6%) at 3 months was not statistically significant ($P = 0.2353$). Numerically more patients in Group II remained relapse-free compared with Group I between Months 4 to 6 (82.3% vs. 70.9%) and within the total observation period of 6 months (69.1% vs. 57.5%); none of these differences reached statistical significance between groups.

Steroids may be used to treat acute relapses during pregnancy and in the post-partum period in nursing women (see Multiple Sclerosis, Acute Severe Exacerbation).

IVIG is not recommended for maintenance treatment to prevent relapses. (See Conditions Not Recommended for Approval.)

Dosing in Multiple Sclerosis (MS), Post-partum. *Dosing must meet ONE of the following (A, B, OR C):*

- A) IVIG 0.15 g per kg as an IV infusion on Day 1 post-partum;⁹¹ OR
- B) IVIG 0.9 g per kg IV infusion given in 3 divided doses over 3 days (post-partum Day 1: 0.45 g per kg, Day 2: 0.3 g per kg, Day 3: 0.15 g per kg);⁹¹ OR
- C) Initial IVIG doses given post-partum as in A) or B), and then 0.15 g per kg every 4 weeks for up to 5 doses (total 6 months of therapy).⁹¹

Initial Approval/Extended Approval.

- A) *Initial Approval.* Approve for 6 months.
- B) *Extended Approval.* Patients may receive a second 6-month course of therapy if they are not taking a DMT for MS.

Duration of Therapy in Multiple Sclerosis (MS), Post-partum. Maximum duration is up to 12 months.

Most patients require 6 months of therapy. Rarely patients may continue for a total of 12 months.

Labs/Diagnostics. None required.

22. Myasthenia Gravis.

Criteria. *The patient must meet the following criteria (A AND B):*

- A) IVIG is prescribed by or in consultation with a neurologist; AND
- B) One of the following applies (i or ii):
 - i. Short-term therapy. Approve IVIG for ONE of the following (a, b, c, or d):
 - a) The patient has an exacerbation of myasthenia gravis;³⁶ OR
 - b) The patient requires stabilization of myasthenia gravis before surgery;³⁶ OR
 - c) The patient has been started on an immunosuppressive drug (e.g., azathioprine, cyclosporine, cyclophosphamide, mycophenolate mofetil, MTX, tacrolimus)^{92,127} and is waiting for full effect; OR
 - d) The patient is starting therapy with a corticosteroid and IVIG is being given to prevent or minimize exacerbations.¹²⁷ OR
 - ii. Maintenance therapy. Approve IVIG if the patient meets the following criteria (a, b, and c):¹²⁷
 - a) The patient has refractory myasthenia gravis; AND
 - b) The patient has tried pyridostigmine; AND
 - c) The patient has tried immunosuppressive therapy with at least one of the following agents: azathioprine, cyclosporine, cyclophosphamide, mycophenolate mofetil, MTX, or tacrolimus AND has had an inadequate response.

Note: Patients with myasthenia gravis crisis are hospitalized. Crisis is defined by respiratory failure resulting from myasthenic weakness and necessitating assisted ventilation.

Recommendations from an international consensus guidance statement for management of adult or juvenile myasthenia gravis include the use of IVIG in some patients.¹²⁷ Symptomatic and immunosuppressive treatment of myasthenia gravis includes pyridostigmine as initial therapy in most patients. Corticosteroids or immunosuppressive therapies are used in all patients with myasthenia gravis who have not met treatment goals after an adequate trial of pyridostigmine. A nonsteroidal immunosuppressive agent (e.g., azathioprine, cyclosporine, mycophenolate mofetil, MTX, tacrolimus) should be used alone when corticosteroids are contraindicated or refused. A nonsteroidal immunosuppressive agent may be used initially in combination with corticosteroids in patients with a high risk of steroid adverse effects. Also, nonsteroidal immunosuppressive agents should be added to corticosteroids if steroid adverse effects are significant, if the response to steroids is inadequate, or if the dose of the corticosteroid cannot be reduced because symptoms recur. In patients with *refractory myasthenia gravis*, chronic IVIG and chronic plasma exchange (PLEX), cyclophosphamide, or Rituxan may be used. PLEX and IVIG are recommended as *short-term* treatments in patients with myasthenia gravis with life-threatening effects such as respiratory insufficiency or dysphagia; to prepare for surgery in patients with significant bulbar dysfunction; when rapid response is needed; when other treatments are not adequate; and before starting corticosteroids if necessary to prevent or minimize exacerbations. The choice of PLEX or IVIG depends on patient factors and the availability of each. PLEX and IVIG are probably equally effective in the therapy of severe generalized myasthenia gravis. The efficacy of IVIG is less certain in milder cases of myasthenia gravis or in ocular myasthenia gravis. PLEX may be more effective than IVIG in muscle specific tyrosine kinase myasthenia gravis. IVIG can be considered as *maintenance therapy* in patients with refractory myasthenia gravis or in patients with relative contraindications to immunosuppressive agents. Refractory myasthenia gravis is defined as the post intervention status is unchanged or worse after corticosteroids and at least two other immunosuppressive agents used in adequate doses for an adequate duration, with persistent symptoms or side effects that limit functioning as defined by the patient or physician. There are no randomized controlled trials regarding the value of using IVIG as maintenance therapy. PLEX and IVIG are used as short-term treatment for *impending and manifest myasthenic crisis and in patients with significant respiratory or bulbar dysfunction*. These patients are hospitalized. In pregnant patients, PLEX or IVIG is used when a prompt but temporary response is needed.

IVIG is used as short-term therapy until more effective long-term immunosuppression can be achieved for patients with severe myasthenic exacerbations or in preparation for surgery.³⁶ In one randomized study, IVIG 0.4 g/kg for either 3 or 5 days was similar in efficacy to plasma exchange in patients with severe exacerbations of myasthenia gravis.⁹⁴ IVIG may be considered in patients with severe myasthenia gravis to treat acute severe decompensation when other treatments have been unsuccessful or are contraindicated.³⁶ In one randomized, double-blind, placebo-controlled trial in 51 patients (not hospitalized) with myasthenia gravis and worsening weakness, IVIG-treated patients had a clinically meaningful improvement in the Quantitative Myasthenia Gravis (QMG) Score for Disease Severity at Day 14 and Day 28.⁹⁵ The greatest improvement occurred in patients with more severe disease (QMG Score for Disease Severity > 10.5).

Dosing in Myasthenia Gravis. Dosing must meet ONE of the following (A OR B):

- A)** Short-term use: 2 g per kg given in divided doses over 2 to 5 consecutive days as an IV infusion,^{36,95,127} OR

- B) Maintenance therapy: 0.4 to 1 g per kg every 4 weeks.¹²⁷

The international consensus guidance statement for management of adult or juvenile myasthenia gravis¹²⁷ recommends an initial dose of IVIG 2 g/kg given in divided doses over 2 to 5 days. For maintenance therapy, the recommended dose is 0.4 to 1 g/kg given every 4 weeks; an attempt to decrease frequency can be made over time. If additional treatment is required, the dose should be adjusted based on the response.

Initial Approval/Extended Approval.

A) Initial Approval.

For short-term use for severe exacerbations and as a short-term measure, approve for one treatment course of 2 g per kg divided over 2 to 5 consecutive days.

For maintenance therapy, approve for 1 year.

B) Extended Approval.

For short-term use, extended approval is not recommended. The patient may relapse and require an additional short-term therapy.

For maintenance therapy, approve for 1 year if the patient is responding according to the prescribing physician.

IVIG is usually used for severe exacerbations and as a short-term measure.^{36,127} For short-term (acute use), the maximum dose per course is 2 g per kg given in divided doses.

Duration of Therapy in Myasthenia Gravis:

A) For short-term use, up to 5 days (as above in dosing).

B) For maintenance therapy, as long as the patient continues to respond according to the prescribing physician.

Some patients may require additional doses for treatment of severe exacerbations.

Labs/Diagnostics. None required.

23. Passive Immunization for Measles (Post-Exposure Prophylaxis).

Criteria. The patient must meet the following criteria (A OR B):

A) The patient is pregnant and meets the following criteria (i and ii); OR

i. The patient has been exposed to measles and IVIG will be given within 6 days of exposure;

ii. The patient does not have evidence of immunity to measles (i.e., the patient does not have a history of the disease or age-appropriate vaccination).

B) The patient is severely immunocompromised (e.g., patients with a bone marrow transplant, graft-versus-host disease [GVHD], acute lymphoblastic leukemia [ALL], acquired immunodeficiency syndrome [AIDS], human immunodeficiency virus [HIV]-infected patients) according to the prescribing physician, AND the patient has been exposed to measles and IVIG will be given within 6 days of exposure.

Note: For patients with primary immune deficiency, see criteria for Immunodeficiency, Primary Humoral: Dosing.

When administered within 6 days of exposure, IG can prevent or modify measles in patients who are nonimmune.¹³ IG therapy is not indicated in persons who have received one dose of measles-containing vaccine at age ≥ 12 months, unless they are severely immunocompromised. IG therapy should not be used to control measles outbreaks, but is used to reduce the risk of infection and complications in the person receiving it. IG therapy has not been shown to prevent rubella or mumps infection after exposure and is not recommended for that purpose.

The ACIP recommends the use of IG therapy for post-exposure prophylaxis of measles in the following patients who are at risk for severe disease and complications from measles: infants less than 12 months of age; pregnant women without evidence of measles immunity; and severely immunocompromised persons.¹³ IM IG can be given to other persons who do not have evidence of measles immunity, but priority is given to persons exposed in settings with intense, prolonged, close contact. For patients exposed without evidence of measles immunity, a rapid IgG antibody test can be used to inform immune status, if administration of IG is not delayed. For *infants aged < 12 months* IM IG is used; infants aged 6 through 11 months can receive MMR vaccine instead of IG if given within 72 hours of exposure. *Pregnant women* without evidence of measles immunity who are exposed to measles should receive IVIG. *Severely Immunocompromised patients* who are exposed to measles should receive IVIG prophylaxis regardless of immunologic or vaccination status because they may not be protected by the vaccine. Severely immune compromised patients include patients with severe primary immunodeficiency; patients who have received a bone marrow transplant until at least 12 months after finishing all immunosuppressive treatment or longer in patients with GVHD; patients on treatment for ALL within and until at least 6 months after completion of immunosuppressive chemotherapy; and patients with AIDS or HIV-infected persons with severe immunosuppression (defined as CD4 percent < 15% [all ages] or CD4 count < 200 lymphocytes/mm³ [aged > 5 years]) and those who have not received MMR vaccine since receiving effective antiretroviral therapy. Some experts include HIV-infected persons who lack recent confirmation of immunologic status or measles immunity.

Dosing for Passive Immunization for Measles. Dosing must meet the following: 0.4 g per kg IV infusion administered one time as soon as possible after exposure.¹³

The ACIP recommends 400 mg/kg as an IV infusion.¹³

Initial Approval/Extended Approval.

- A) Initial approval. 1 day (one dose).
- B) Extended approval. Not recommended.

Duration of Therapy for Passive Immunization of Measles: 1 day (one dose).

Labs/Diagnostics. None required.

24. Passive Immunization for Varicella (Chickenpox) [Post-Exposure Prophylaxis].

Criteria. *The patient must meet the following criteria (A OR B):*

- A)** The patient is a HIV-infected infant or child and meets the following criteria (i, ii, iii, and iv):
- i. IVIG is prescribed by or in consultation with an infectious diseases specialist or an immunologist; AND
 - ii. The patient is < 13 years of age; AND
 - iii. VariZIG® (varicella zoster immune globulin [human] for IM injection) is not available;⁹⁶ AND
 - iv. The patient does not have evidence of immunity to varicella (i.e., patient does not have a history of the disease or age-appropriate vaccination); OR
- B)** The patient is not an HIV-infected infant or child and meets the following criteria (i, ii, iii and iv):
- i. IVIG is prescribed by or in consultation with an infectious diseases specialist or immunologist; AND
 - ii. VariZIG (varicella zoster immune globulin [human] for IM injection) is not available; AND
 - iii. The patient does not have evidence of immunity to varicella (i.e., patient does not have a history of the disease or age-appropriate vaccination); AND
 - iv. The patient meets one of the following criteria (a or b):
 - a) The patient is immune compromised; OR
 - b) The patient is pregnant.

HIV-infected children without a history of previous chickenpox or children who have not received two doses of varicella vaccine should receive VariZIG or, if not available, IVIG within 10 days (ideally within 4 days) after close contact with a person who has chickenpox or shingles.⁸⁰ Post-exposure prophylaxis with VariZIG, or if VariZIG is not available, IVIG should be considered for HIV-infected children with moderate-to-severe immune compromise even if they have been immunized with varicella vaccine. Children who have received IVIG within 2 or 3 weeks of exposure do not require additional passive immunization.⁷⁹⁻⁸⁰

VariZIG is indicated for post-exposure prophylaxis in certain patients without immunity to varicella and is given as soon as possible after exposure, preferably within 4 days, and as late as 10 days after exposure.^{79,96-98} Whether to administer VariZIG depends on three factors: 1) whether the patient lacks evidence of immunity to varicella; 2) whether the exposure is likely to result in infection; and 3) whether the patient is at greater risk for varicella complications than the general population.⁹⁸ Patients without evidence of immunity to varicella who are at high risk for severe varicella and complications, who have been exposed to varicella or herpes zoster, and for whom varicella vaccine is contraindicated should receive VariZIG. The following patient groups are recommended by the Centers for Disease Control and Prevention (CDC) to receive VariZIG: 1) immunocompromised patients without evidence of immunity; 2) newborn infants whose mothers have signs and symptoms of varicella around the time of delivery (i.e., 5 days before to 2 days after) [these babies are probably hospitalized]; 3) hospitalized premature infants born at ≥ 28 weeks of gestation whose mothers do not have evidence of immunity to varicella; 4) hospitalized premature infants born at < 28 weeks gestation or who weigh ≤ 1,000 g at birth, regardless of their mothers' evidence of immunity to varicella; and 5) pregnant women without evidence of immunity.⁹⁸ In situations where administration of VariZIG does not appear possible within 10 days of

exposure, IVIG is considered an alternative and should be given within 10 days of exposure⁹⁶ (and ideally within 96 hours after exposure).⁷⁹ The dose is 400 mg/kg given once.^{79,96} Patients who have received IVIG 400 mg/kg within the prior 3 weeks should be protected.⁷⁹ For pregnant women who cannot receive VariZIG, clinicians can choose either IVIG or closely monitor the women for signs or symptoms of varicella and institute acyclovir therapy if illness occurs.⁹⁶

Dosing for Passive Immunization for Varicella. Dosing must meet the following: 0.4 g per kg IV infusion administered one time.^{79-80,96}

Initial Approval/Extended Approval.

- A) Initial Approval. 1 day (one dose).^{79-80,96}
- B) Extended Approval. Not recommended.

Duration of Therapy for Passive Immunization for Varicella. 1 day (one dose).

Labs/Diagnostics. None required.

25. Pure Red Blood Cell Aplasia (PRCA) Secondary to Chronic [Persistent] Parvovirus B19 Infection.

Criteria. The patient must meet the following criteria (A, B, AND C):

- A) IVIG is prescribed by or in consultation with an infectious diseases specialist, immunologist, hematologist, or transplant specialist; AND
- B) The patient has a chronic immunodeficiency condition (e.g., patients with HIV infection, solid organ transplants [e.g., renal, liver], chemotherapy for hematologic malignancy);^{92,99} AND
- C) The patient has clinically significant anemia as determined by the prescribing physician OR the patient is transfusion dependent.⁹²

In *immunosuppressed* patients lacking neutralizing antibodies, IVIG has been useful for the treatment of persistent B19 infection.^{33,100} IVIG has been used to treat severe anemia secondary to chronic B19 infection in the context of solid-organ transplantation, HIV infection, or primary antibody deficiency. Three to five days of IVIG induces an increase in reticulocyte count with an accompanied rise in the hemoglobin level, and is often curative in that B19 is cleared from the body.^{92,100} Persistent B19 infection in apparently *immunocompetent* individuals who possess neutralizing antibodies does not respond well to IVIG.¹⁰⁰ In immunocompetent children, adolescents and adults, parvovirus B19 is self-limiting and does not require treatment with IVIG.⁹⁹ PRCA and the underlying persistent parvovirus B19 infection may be terminated rapidly by discontinuing immunosuppressive therapy or by instituting antiretroviral therapy in patients with AIDS. IVIG has been curative in patients with congenital immunodeficiency, but in patients with AIDS, parvovirus often persists at lower levels; relapses of anemia may require repeated administration of immunoglobulin. Maintenance therapy has been used in patients who relapse.⁹²

Dosing for Pure Red Blood Cell Aplasia (PRCA) Secondary to Chronic Parvovirus B19. Dosing must meet the following (A OR B):

- A) 2 g per kg as an IV infusion given over a period of 2 to 5 consecutive days (one course) for up to two courses;^{92,99-100} OR
- B) 0.4 to 0.5 g per kg daily for 5 days.⁵¹

A second course of IVIG may be required based on hemoglobin response. More than 2 courses of IVIG are rarely indicated. Response is measured by increase in hemoglobin and reticulocytosis.

Initial Approval/Extended Approval.

- A) *Initial Approval.* Approve for 2 months.
- B) *Extended Approval.*
 - i. Approve additional single courses of IVIG 2 g per kg given in divided doses over 2 to 5 consecutive days if the patient responded with an increase in hemoglobin to a previous course of IVIG, but relapses when off IVIG;⁹² OR
 - ii. Approve maintenance therapy with IVIG 0.4 g per kg every 4 week to prevent relapse in patients who continue to be immunocompromised⁹² and who have responded with an increase in hemoglobin to previous courses of IVIG.

After 2 months (or two courses of IVIG), patients are evaluated for an increase in hemoglobin. If there is no improvement according to the prescribing physician, then further authorization is not recommended. IVIG is rarely indicated for more than 2 months in a row.

Duration of Therapy for Pure Red Blood Cell Aplasia (PRCA) Secondary to Chronic Parvovirus B19: IVIG therapy may continue in patients who relapse, or maintenance therapy can continue to prevent relapse in patients who are still infected with parvovirus and who are immunosuppressed.

If parvovirus becomes undetectable, IVIG should be discontinued. When/if the underlying immunosuppression is reversed (e.g., when immunosuppressive therapy is discontinued, tacrolimus is replaced with cyclosporine, or HIV-infected patients are treated with antiretroviral therapy), IVIG should be discontinued.

Labs/Diagnostics. None required.

26. Pure Red Blood Cell Aplasia (PRCA), Immunologic Subtype.

Criteria. *The patient must meet the following criteria (A, B, AND C):*

- A) IVIG is prescribed by or in consultation with an infectious diseases specialist, immunologist, hematologist, or transplant specialist; AND
- B) The patient has tried a systemic corticosteroid (e.g., prednisone);³³ AND
- C) The patient has tried either cyclophosphamide OR cyclosporine.³³

The Canadian expert panel of hematologists recommends prednisone followed by cyclophosphamide or cyclosporine as first-line therapy for immunologic type PRCA.³³ Based on case reports about 50% of patients have an initial benefit with IVIG therapy. This panel considers IVIG a reasonable second-line option since this is a serious condition. The immunologic subtype mechanism may be humoral or

cellular and can be caused by tumors, certain drugs (e.g., azathioprine, carbamazepine), connective tissue disorders, and incompatible bone marrow transplant.

Dosing in Pure Red Cell Aplasia (PRCA), Immunologic Subtype. Dosing must meet the following: 0.5 g per kg IV infusion every week for 4 weeks.³³

Very limited information is available because this condition is uncommon.

Initial Approval/Extended Approval.

- A) Initial Approval. Approve for 4 weeks of therapy.
- B) Extended Approval. Approve a second 4-week course if the patient has responded with an increase in hemoglobin and reticulocytosis, according to the prescribing physician.

Duration of therapy in Pure Red Cell Aplasia (PRCA), Immunologic Subtype. Up to 2 months.

Labs/Diagnostics. None required.

27. Stiff-Person Syndrome (Moersch-Woltman Syndrome).

Criteria. The patient must meet the following criteria (A AND B):

- A) IVIG is prescribed by or in consultation with a neurologist; AND
- B) The patient meets one of the following criteria (i or ii):
 - i. The patient has tried a benzodiazepine (e.g., diazepam) OR baclofen; OR
 - ii. The patient has contraindications to both a benzodiazepine AND baclofen according to the prescribing physician.

In one double-blind, placebo-controlled crossover trial in 16 patients with stiff-person syndrome, IVIG 2 g/kg divided into two consecutive daily doses and given once monthly for 3 months, decreased stiffness scores significantly and decreased heightened sensitivity scores.^{36,55,101}

Dosing for Stiff-Person Syndrome. Dosing must meet the following (A OR B):

- A) 2 g per kg IV infusion given over a period of 2 to 5 consecutive days every month,^{36,55,101} OR
- B) For maintenance therapy, the dose of IVIG is adjusted to provide the minimum effective dosage of IVIG. The maximum dose is 2 g per kg.

Initial Approval/Extended Approval.

- A) Initial Approval. Approve for 3 months.
- B) Extended Approval. Approve for 12 months, if the patient has responded (such as reduced stiffness or frequency of spasms, ability to walk unassisted) according to the prescribing physician.

Duration of Therapy for Stiff-Person Syndrome. IVIG therapy may continue as long as there is continuing objective clinical improvement as determined by the prescribing physician.

Labs/Diagnostics. None required.

28. Thrombocytopenia, Fetal Alloimmune.

Criteria. *The patient must meet the following criteria (A AND B):*^{33,102}

- A)** The patient is pregnant and receiving antenatal therapy; AND
- B)** IVIG is prescribed by or in consultation with a hematologist or an obstetrician.

Antenatal therapy with IVIG administered to the mother is effective in increasing fetal platelet counts in neonatal alloimmune thrombocytopenia (NAIT).¹⁰²⁻¹⁰⁵ IVIG reduces the risk of intracranial hemorrhage (ICH) and increases the fetal platelet count. In one prospective, multicenter study, 73 women with alloimmune thrombocytopenia who had *not* delivered an infant with an ICH in a prior pregnancy were randomized to receive either IVIG 2 g/kg/week (group A) or IVIG 1 g/kg/week plus prednisone 0.5 mg/kg/day (group B), starting at about 20 weeks of gestation.¹⁰³ Fetal blood sampling was performed at about 32 weeks of gestation and, if the fetal platelet count was < 30,000 per mm³ or cordocentesis could not be done, salvage therapy was given. Salvage therapy in patients in group A was addition of prednisone 0.5 mg/kg/day and in patients in group B was increasing IVIG to 2 g/kg/week in addition to the prednisone they were already taking. One neonate in each group suffered an ICH (primary outcome variable) during the neonatal period and neither was due to treatment failure. At the time of fetal blood sampling, the average platelet counts were 121,600 per mm³ in group A and 116,100 per mm³ in group B. The average birth platelet counts were 169,400 per mm³ in group A and 134,000 per mm³ in group B. In all, 27% of patients in group A and 17% of patients in group B received salvage therapy. Randomized controlled trials comparing IVIG or steroids vs. no treatment alone have not been done because of the known risk of ICH.¹⁰⁴

First-line therapy for newborns with fetal/neonatal alloimmune thrombocytopenia is antigen-negative compatible platelets; IVIG is adjunctive.³³

Dosing in Antepartum Treatment of Fetal Alloimmune Thrombocytopenia. *Dosing must meet ONE of the following (A OR B):*

- A)** IVIG 1 g per kg as an IV infusion every week;^{33,102-103} OR
- B)** IVIG 2 g per kg IV infusion every week or 1 g per kg twice weekly.¹⁰²⁻¹⁰³

Initial Approval/Extended Approval.

- A)** *Initial Approval.* Approve for up to 6 months.
- B)** *Extended Approval.* Not recommended.

Duration of Approval in Antepartum Treatment of Fetal Alloimmune Thrombocytopenia. Up to 6 months.

Antenatal therapy usually consists of IVIG and prednisone started between 12 and 20 weeks gestation, and then elective delivery at 37 to 38 weeks gestation.¹⁰⁵

Lab/Diagnostics. None required.

Waste Management for All Indications. Vials of IVIG are available in many sizes and concentrations. The dose should be calculated and the number of vials needed assessed.

Conditions Not Recommended for Approval

IVIG has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. Rationale for non-coverage for these specific conditions is provided below. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval.)

1. **Adrenoleukodystrophy.** Evidence does not support IVIG use.^{18,36,92} Only one small study (n = 12) is available; IVIG did not arrest disease progression.¹⁰⁶
2. **Alzheimer's Disease (AD).** In one multicenter, double-blind, Phase III, placebo-controlled trial, 390 patients with mild to moderate AD were randomized to therapy with IVIG 400 mg/kg or 200 mg/kg or to placebo given every 2 weeks for 18 months.^{107,120} There was no statistically significant difference in the rate of cognitive decline when compared to placebo (mean 7.4 in the 400 mg/kg group; 8.9 in the 200 mg/kg group; 8.4 in the placebo group). There was not a statistically significant change in functional ability when compared to placebo (mean of -11.4 in the 400 mg/kg group; -12.4 in the 200 mg/kg group; -11.4 in the placebo group). Large placebo-controlled trials with a longer observation period are needed to establish efficacy, determine the optimal dosing regimen, and to confirm the safety of IVIG in the general AD population.¹⁰⁸⁻¹⁰⁹
3. **Amyotrophic Lateral Sclerosis.** There is insufficient evidence to recommend IVIG.^{18,36,110-111} Only case series are available; no improvement in muscle strength was observed.¹¹⁰⁻¹¹¹
4. **Anemia, Aplastic.** Evidence does not support IVIG use.^{33,92}
5. **Asthma.** Global Initiative for Asthma (GINA) guidelines for asthma management and prevention do not include recommendations for use of IVIG.¹¹²
6. **Atopic Dermatitis.** Evidence does not support IVIG use. According to a practice parameter endorsed by the AAAAI; the ACAAI; and the Joint Council of Allergy, Asthma and Immunology, use of IVIG to treat severe refractory atopic dermatitis has produced conflicting results.¹¹³ Most studies are not controlled and included small numbers of patients. According to the practice parameter, although children appear to have a better response than adults, controlled studies are needed to answer the question of efficacy in a more definitive manner. In one randomized, placebo-controlled study, children (n = 40) with moderate to severe atopic dermatitis received three injections of IVIG 2 g/kg or placebo every month over a 12-week period.¹¹⁴ The disease severity index was significantly decreased 3 months after completing treatments compared with baseline values (P < 0.05), but improvement had decreased by 6 months after therapy. Guidelines from the American Academy of Dermatology state that there is insufficient data to make a recommendation for the use of IVIG in the management of atopic dermatitis.¹¹⁵ Double-blind, placebo-controlled trials that are at least 4 months long and that are powered to show whether IVIG is effective are needed.



	<p>77. Ambler KL, Vickars LM, Leger CS, et al. Clinical features, treatment, and outcome of HIV-associated immune thrombocytopenia in the HAART era. <i>Adv Hematol.</i> 2012;2012:910954.</p> <p>78. WinRho® SDF solution for injection [prescribing information]. Berwyn, PA: Aptevo BioTherapeutics LLC; August 2016.</p> <p>79. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children. Department of Health and Human Services. Last review June 27, 2018. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatics.pdf Accessed on July 6, 2018.</p> <p>80. American Academy of Pediatrics. Human Immunodeficiency Virus Infection. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. <i>Red Book®: 2018 Report of the Committee on Infectious Diseases.</i> American Academy of Pediatrics; 2018:459-476.</p> <p>81. Mouthon L, Lortholary O. Intravenous immunoglobulins in infectious diseases: where do we stand? <i>Clin Microbiol Infect.</i> 2003;9:333-338.</p> <p>82. Spector SA, Gelber RD, McGrath N, et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. <i>N Engl J Med.</i> 1994;331:1181-1187.</p> <p>83. Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome (review). <i>Cochrane Database Syst Rev.</i> 2011(2):CD003279.</p> <p>84. Juel VC. Treatment use of 3,4-Diaminopyridine. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2017 Apr 14]. Available from: https://clinicaltrials.gov/show/NCT01765140 NLM Identifier: NCT 01765140.</p> <p>85. The NCCN Multiple Myeloma Clinical Practice Guidelines in Oncology (Version 4.2018 – February 12, 2018). © 2018 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org Accessed on June 8, 2018.</p> <p>86. Snowden JA, Ahmedzai SH, Ashcroft J, et al; Haemato-oncology Task Force of British Committee for Standards in Haematology and UK Myeloma Forum. Guidelines for supportive care in multiple myeloma 2011. <i>Br J Haematol.</i> 2011;154:76-103.</p> <p>87. National Multiple Sclerosis Society. Relapse management. Available at: http://www.nationalmssociety.org/For-Professionals/Clinical-Care/Managing-MS/Relapse-Management Accessed on June 8, 2018.</p> <p>88. Drugs and lactation database of the National Library of Medicine's TOXNET system (Globulin, Immune in Lactmed). Available at: https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/f?./temp/~SeMjST:1. Accessed on June 8, 2018.</p> <p>89. Hellwig K, Beste C, Schimrigk S and Chan A. Immunomodulation and postpartum relapses in patients with multiple sclerosis. <i>Ther Adv Neurol Disord.</i> 2009;2:7-11.</p> <p>90. Vukusic S, Hutchinson M, Hours M, et al and the Pregnancy in Multiple Sclerosis Group. Pregnancy and multiple sclerosis (the PRIMs study): clinical predictors of post-partum relapse. <i>Brain.</i> 2004;127:1353-1360.</p> <p>91. Haas J, Hommes OR. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. <i>Mult Scler.</i> 2007;13:900-908.</p> <p>92. British Columbia Blood Coordinating Office. IVIG utilization management handbook. 1st Ed. British Columbia, Canada: Provincial Blood Coordinating Office; April 2002. British Columbia Blood Coordinating Office. Intravenous Immune Globulin (IVIG) Utilization Management Program Guidelines. Available at http://www.pbco.ca/images/Blood_Products/IVIG/Resources/ivighandbook-combined.pdf. Accessed on July 2, 2018.</p> <p>93. Lejeune A, Martin L, Santibanez S, et al. Postexposure prophylaxis with intravenous immunoglobulin G prevents infants from getting measles. <i>Acta Paediatr.</i> 2017;106(1):174-177.</p>
--	---

	<p>94. Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. <i>Ann Neurol.</i> 1997;41:789-796.</p> <p>95. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. <i>Neurology.</i> 2007;68:837-841.</p> <p>96. American Academy of Pediatrics. Varicella-Zoster Infections.—In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book®: 2018 Report of the Committee on Infectious Diseases. American Academy of Pediatrics; 2018:869-883.</p> <p>97. VariZIG® for intramuscular injection [prescribing information]. Berwyn, PA: Aptevo BioTherapeutics LLC; August 2016.</p> <p>98. Centers for Disease Control and Prevention. Updated recommendations for use of VariZIG – United States, 2013. <i>MMWR.</i> 2013;62:574-576.</p> <p>99. Young NS, Brown KE. Mechanisms of disease: Parvovirus B19. <i>N Engl J Med.</i> 2004;350:586-597.</p> <p>100. Broliden K, Tolfvenstam T, Norbeck O. Clinical aspects of parvovirus B19 infection. <i>J Intern Med.</i> 2006;260:285-304.</p> <p>101. Dalakas MC, Fujii M, Li M, et al. High-dose intravenous immune globulin for stiff-person syndrome. <i>N Engl J Med.</i> 2001;345:1870-1876.</p> <p>102. Berkowitz RL, Kolb EA, McFarland JG, et al. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. <i>Obstet Gynecol.</i> 2006;107:91-96.</p> <p>103. Berkowitz RL, Lesser ML, McFarland JG, et al. Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial. <i>Obstet Gynecol.</i> 2007;110(2 Pt 1):249-255.</p> <p>104. Symington A, Paes B. Fetal and neonatal alloimmune thrombocytopenia: harvesting the evidence to develop a clinical approach to management. <i>Am J Perinatol.</i> 2011;28:137-144.</p> <p>105. Townsley DM. Hematologic complications of pregnancy. <i>Semin Hematol.</i> 2013;50:222-231.</p> <p>106. Cappa M, Bertini E, del Balzo P, et al. High dose immunoglobulin IV treatment in adrenoleukodystrophy. <i>J Neurol Neurosurg Psychiatry.</i> 1994;57 Suppl:69-70.</p> <p>107. Baxter announces topline results of phase III study of immunoglobulin for Alzheimer's disease [press release]. Deerfield, IL: Baxter International Inc; May 7, 2013. Available at: https://investor.baxter.com/investors/events-and-news/news/press-release-details/2013/Baxter-Announces-Topline-Results-of-Phase-III-Study-of-Immunoglobulin-for-Alzheimers-Disease/default.aspx. Accessed on June 8, 2018.</p> <p>108. Fillit H, Hess G, Hill J, et al. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. <i>Neurology.</i> 2009;73:180-185.</p> <p>109. Dodel R, Rominger A, Bartenstein P, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. <i>Lancet Neurol.</i> 2013;12:233-243.</p> <p>110. Meucci N, Nobile-Orazio E, and Scarlato G. Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis. <i>J Neurol.</i> 1996;243:117-120.</p> <p>111. Dalakas MC, Stein DP, Otero C, et al. Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy. <i>Arch Neurol.</i> 1994;51:861-864.</p> <p>112. <i>From the Global Strategy for Asthma Management and Prevention</i>, Global Initiative for Asthma (GINA) 2017 2015. Available from: http://www.ginasthma.org/. Accessed on June 13, 2018.</p> <p>113. Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter update 2012. <i>J Allergy Clin Immunol.</i> 2013;131:295-9.e1-27. Available at: http://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Practice%20and%20Parameters/Atopic-dermatitis-2013.pdf Accessed on June 8, 2018.</p>
--	---

	<p>114. Jee SJ, Kim JH, Baek HS, et al. Long-term efficacy of intravenous immunoglobulin therapy for moderate to severe childhood atopic dermatitis. <i>Allergy Asthma Immunol Res.</i> 2011;3:89-95.</p> <p>115. Sidbury R, Davis DM, Cohen DE, et al; American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. <i>J Am Acad Dermatol.</i> 2014;71:327-349.</p> <p>116. Vollmer-Conna U, Hickie I, Hadzi-Pavlovic D, et al. Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome. <i>Am J Med.</i> 1997;103:38-43.</p> <p>117. Goebel A, Baranowski A, Maurer K, et al. Intravenous immunoglobulin treatment of the complex regional pain syndrome: a randomized trial. <i>Ann Intern Med.</i> 2010;152:152-158.</p> <p>118. Chrissafidou A, Malek M, Musch E. Experimental study on the use of intravenous immunoglobulin (IVIg) in patients with steroid-resistant Crohn's disease. <i>Z Gastroenterol.</i> 2007;45:605-608.</p> <p>119. Balfour-Lynn IM, Mohan U, Bush A and Rosenthal M. Intravenous immunoglobulin for cystic fibrosis lung disease: a case series of 16 children. <i>Arch Dis Child.</i> 2004;89:315-319.</p> <p>120. Relkin NR, Thomas RG, Rissman RA et al. A phase 3 trial of IV immunoglobulin for Alzheimer disease. <i>Neurology.</i> 2017; 88(18):1768-1775.</p> <p>121. Goebel A, Bisla J, Carganillo R, et al. Low-dose intravenous immunoglobulin treatment for long-standing complex regional pain syndrome: A randomized trial. <i>Ann Intern Med.</i> 2017;167(7):476-483.</p> <p>122. Colagiuri S, Leong GM, Thayer Z, et al. Intravenous immunoglobulin therapy for autoimmune diabetes mellitus. <i>Clin Exp Rheumatol.</i> 1996;14 Suppl 15:S93-97.</p> <p>123. Heinze E. Immunoglobulins in children with autoimmune diabetes mellitus. <i>Clin Exp Rheumatol.</i> 1996;14 Suppl 15:S99-102.</p> <p>124. Geng J, Dong J, Li Y, et al. Intravenous immunoglobulin for epilepsy. <i>Cochrane Database of Systemic Reviews.</i> 2011;1:CD008557.</p> <p>125. Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: Report of the Guideline Committee of the American Epilepsy Society. <i>Epilepsy Curr.</i> 2016;16:48-61.</p> <p>126. Caro XJ, Winter EF, Dumas AJ. A subset of fibromyalgia patients have findings suggestive of chronic inflammatory demyelinating polyneuropathy and appear to respond to IVIg. <i>Rheumatology (Oxford).</i> 2008;47:208-211.</p> <p>127. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. <i>Neurology.</i> 2016;87(4):419-425. Available at: http://www.neurology.org/content/87/4/419.full.pdf+html. Accessed on June 13, 2018. Data supplement available at: http://www.neurology.org/content/87/4/419/suppl/DC1. Accessed on June 8, 2018.</p> <p>128. Aukrust P, Yndestad A, Ueland T, et al. The role of intravenous immunoglobulin in the treatment of chronic heart failure. <i>In. J Cardiol.</i> 2006;112:40-45.</p> <p>129. Cordonnier C, Chevret S, Legrand M, et al; GREFIG Study Group. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. <i>Ann Intern Med.</i> 2003;139:8-18.</p> <p>130. Kuhar DT, Henderson DK, Struble KA, et al; US Public Health Service Working Group. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Published 9/25/2013. Available at: http://stacks.cdc.gov/view/cdc/20711 Accessed on June 8, 2018.</p>
--	--

	<p>131. Comi G, Roveri L, Swan A, et al; Inflammatory Neuropathy Cause and Treatment Group. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. <i>J Neurol.</i> 2002;249:1370-1377.</p> <p>132. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. <i>J Peripher Nerv Syst.</i> 2010;15:185-195.</p> <p>133. Practice Committee of American Society for Reproductive Medicine. Anti-phospholipid antibodies do not affect IVF success. <i>Fertil Steril.</i> 2008;90(5 Suppl):S172-S173.</p> <p>134. Go CY, Mackay MT, Weiss SK, et al; Child Neurology Society; American Academy of Neurology. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. <i>Neurology.</i> 2012;78(24):1974-1980.</p> <p>135. Gray O, McDonnell GV, Forbes RB. Intravenous immunoglobulins for multiple sclerosis. <i>Cochrane Database Syst Rev.</i> 2003;(4):CD002936.</p> <p>136. Hommes OR, Sorensen PS, Fazekas F, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. <i>Lancet.</i> 2004;364:1149-1156.</p> <p>137. Goodin DS, Frohman EM, Garmany GP Jr, et al; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. <i>Neurology.</i> 2002;58:169-178.</p> <p>138. Fazekas F, Lublin FD, Li D, et al; UBC MS/MRI Research Group. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. <i>Neurology.</i> 2008;71:265-271.</p> <p>139. Quaglia M, Stratta P. Idiopathic membranous nephropathy. <i>Drugs.</i> 2009;69:1303-1317.</p> <p>140. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision. <i>J Peripher Nerv Syst.</i> 2010;15:1-9.</p> <p>141. Koopman FS, Beelen A, Gilhus NE, et al Treatment for postpolio syndrome. <i>Cochrane Database of Systematic Reviews.</i> 2015 May 18;5:CD007818.</p> <p>142. Branch DW, Peaceman AM, Druzin M, et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. <i>Am J Obstet Gynecol.</i> 2000;182(1 Pt 1):122-127.</p> <p>143. Stephenson MD, Kutteh WH, Purkiss S, et al. Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebo-controlled trial. <i>Hum Reprod.</i> 2010;25:2203-2209.</p> <p>144. Ata B, Lin Tan S, Shehata F, et al. A systematic review of intravenous immunoglobulin for treatment of unexplained recurrent miscarriage. <i>Fertil Steril.</i> 2011;95:1080-1085.</p> <p>145. The Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. <i>Fertil Steril.</i> 2012;98:1103-1111.</p> <p>146. Fried AJ, Bonilla FA. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. <i>Clin Microbiol Rev.</i> 2009;22:396-414.</p>
--	---

	<p>147. Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. <i>J Allergy Clin Immunol</i>. 2011;127:303-312.</p> <p>148. Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines – application to the individual patient. <i>Kidney Int</i>. 2012;82:840-856.</p> <p>149. Levy Y, Amital H, Langevitz P, et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. <i>Arthritis Rheum</i>. 2004;50:1005-1007.</p> <p>150. Nacci F, Righi A, Conforti ML, et al. Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. <i>Ann Rheum Dis</i>. 2007;66:977-979.</p> <p>151. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. <i>Am J Ophthalmol</i>. 2000;130:492-513.</p> <p>152. Becker MD, Rosenbaum JT. Current and future trends in the use of immunosuppressive agents in patients with uveitis. <i>Curr Opin Ophthalmol</i>. 2000;11:472-477.</p> <p>153. Onal S. Efficacy of intravenous immunoglobulin treatment in refractory uveitis. <i>Ocul Immunol Inflamm</i>. 2006;14:367-374.</p> <p>154. LeHoang P, Cassoux N, George F, et al. Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. <i>Ocul Immunol Inflamm</i>. 2000;8:49-57.</p> <p>155. The NCCN Management of Immunotherapy-Related Toxicities (Immune Checkpoint Inhibitor-Related Toxicities) Clinical Practice Guidelines in Oncology (Version 1.2018 – February 14, 2018). © 2018 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed on June 18, 2018</p> <p>156. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. <i>J Clin Oncol</i>. 2018; 36:1714-1768.</p> <p>157. Garces JC, Biusti S, Giusti S, et al. Antibody-mediated rejection: A review. <i>Ochsner J</i>. 2017;17(1):46-55.</p> <p>158. Wan SS, Ying TD, Wyburn K, et al. The treatment of antibody-mediated rejection in kidney transplantation: An updated systematic review and meta-analysis. <i>Transplantation</i>. 2018;102(4): 557-568.</p> <p>159. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. <i>Am J Transplant</i>. 2009; 9 Suppl 3:S1.</p> <p>160. Witt CA, Gaut JP, Yusen RD, et al. Acute antibody-mediated rejection after lung transplantation. <i>J Heart Lung Transplant</i>. 2013;32:1034.</p> <p>161. Hachem RR, Yusen RD, Meyers BF, et al. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. <i>J Heart Lung Transplant</i>. 2010;29:973.</p> <p>162. Otani S, Davis AK, Cantwell L, et al. Evolving experience of treating antibody-mediated rejection following lung transplantation. <i>Transpl Immunol</i>. 2014;31:75.</p> <p>163. UK National Health Service. Clinical Guidelines for Immunoglobulin Use. 2nd edition. July 2011. http://www.ivig.nhs.uk/clinicinfo.html Accessed June 21, 2018.</p> <p>164. Ueda M, Berger M, Gale RP, et al. Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation. <i>Blood Rev</i>. 2018; 32(2):106-115.</p> <p>OTHER REFERENCES UTILIZED</p> <ul style="list-style-type: none"> • Dalakas MC. Inflammatory muscle diseases. <i>N Engl J Med</i>. 2015;372:1734-1747.
--	---



	<ul style="list-style-type: none"> • Dodel RC, Du Y, Depboylu C, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. <i>J Neurol Neurosurg Psychiatry</i>. 2004;75:1472-1474. • Hack CE, Scheltens P. Intravenous immunoglobulins: a treatment for Alzheimer's disease? <i>J Neurol Neurosurg Psychiatry</i>. 2004;75:1374-1375. • Instituto Grifols, S.A. Study of the efficacy and safety of immune globulin intravenous (human) Flebogamma® 5% DIF in patients with post-polio syndrome (FORCE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2017 Apr 21]. Available at: https://www.clinicaltrials.gov/ct2/show/NCT02176863?term=postpolio+syndrome&rank=3. • Jordan SC, Choi J, Vo A. Achieving incompatible transplantation through desensitization: current perspectives and future directions. <i>Immunotherapy</i>. 2015;7:377-398. • Léger JM, De Bleecker JL, Sommer C, et al; PRIMA study investigators. Efficacy and safety of Privigen^(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study). <i>J Peripher Nerv Syst</i>. 2013;18:130-140. • Lo E, Deane S. Diagnosis and classification of immune-mediated thrombocytopenia. <i>Autoimmun Rev</i>. 2014;13:577-583. • Loeffler DA. Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered? <i>J Neuroinflammation</i>. 2014;11:198. • Lünemann JD, Quast I, Dalakas MC. Efficacy of intravenous immunoglobulin in neurological diseases. <i>Neurotherapeutics</i>. 2016;13:34-46. • Orange JS, Ballou M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. <i>J Allergy Clin Immunol</i>. 2012;130(3 Suppl):S1-24. • Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2012;78:1009-1015. Guideline Reaffirmed July 18, 2015. • Relkin NR, Szabo P, Adamiak B, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer's disease. <i>Neurobiol Aging</i>. 2009;30:1728-1736. • Tinckam KJ, Keshavjee S, Chaparro C, et al. Survival in sensitized lung transplant recipients with perioperative desensitization. <i>Am J Transplant</i>. 2015;15:417-426.
CFR	
WAC	WAC 284-43-2050
RCW	
Contract Citation	<input checked="" type="checkbox"/> WAH
	<input checked="" type="checkbox"/> IMC
	<input checked="" type="checkbox"/> MA
Other Requirements	
NCQA Elements	

Revision History

Revision Date	Revision Description	Revision Made By
07/24/2017	*NEW*	Michael Sporck, Pharmacy Intern Sophia Yun, PharmD
07/25/2017	Approval	MMLT
03/09/2018	Reassigned from UM to PM	Cindy Bush
04/25/2018	Transferred to new template	Cindy Bush
05/22/2018	Revised	Jennifer Farley, PharmD
06/14/2018	Approval	UM Committee
11/27/2018	Revised from ESI Annual update	Jennifer Farley, PharmD
12/12/2018	Approval	UM Committee

Appendix A: Treatment of Patients with ITP

ITP can occur in isolation (primary) or in association with other disorders (secondary) [e.g., autoimmune diseases, viral infections such as hepatitis C and HIV, and certain drugs].⁴¹ An International Working Group (IWG) consensus panel defines primary ITP as a platelet count $< 100,000$ per mm^3 in the absence of other causes or disorders associated with thrombocytopenia. ITP is also defined by time from diagnosis: newly diagnosed (diagnosis to 3 months), persistent (3 months to 12 months from diagnosis), or chronic (lasting for more than 12 months). These definitions may not apply to patients with secondary forms of ITP.

In adults with ITP/IT who are acutely bleeding, American Society of Hematology (ASH) guidelines indicate that if the platelet count is $< 30,000/\text{mm}^3$ initial therapy is systemic corticosteroids.⁴⁰⁻⁴¹ Longer courses of steroids over shorter courses of steroids or IVIG are preferred as first-line treatment in adults because they are associated with a longer time-to-loss of response.⁴¹ IVIG may be used with corticosteroids when a more rapid increase in platelet count is required. IVIG may be added to corticosteroid therapy if thrombocytopenia persists or worsens after about 3 days of corticosteroid therapy.^{33,41} If there is an urgent need to increase the platelet count quickly, IVIG can be started with a corticosteroid.⁴¹

Adults who are at risk for intracerebral bleeding will be hospitalized and treated with a high-dose corticosteroid, IVIG, and platelet transfusions or other modalities.⁴¹

Systemic glucocorticoids have been the standard initial therapy for adults with moderate to severe thrombocytopenia and symptomatic purpura.^{41,44} Evidence for use of glucocorticoids is based on case series and on a small randomized trial that compared glucocorticoid therapy to IVIG and both in combination as initial treatment. According to the ASH guideline, there is limited evidence for basing treatment recommendations on a specific platelet count or age for all patients. Observational data of patients with ITP have suggested that bleeding risk is increased with platelet counts $< 20,000$ or $< 30,000$ per mm^3 , but it is unclear whether offering treatment to all patients with ITP at these levels will result in decreased bleeding. In patients with recurrent or persistent thrombocytopenia associated with bleeding after an initial treatment course with corticosteroids or with IVIG or Rh₀(D) immune globulin, there is no evidence to guide a sequence of treatments.

Splenectomy remains the only treatment that provides sustained remission off all treatments at 1 year and beyond.⁴¹ ASH recommends splenectomy for patients who have failed corticosteroids. Patients who do not achieve spontaneous remission or do not maintain a complete response following cessation of therapy are classified as having persistent (3 to 12 months from diagnosis) or chronic (lasting > 12 months) ITP. Patients who have failed splenectomy or relapsed thereafter and have severe ITP or have a risk of bleeding that requires therapy are classified as having refractory ITP. ASH does not recommend therapy in patients with platelet counts $> 30,000$ per mm^3 in the absence of bleeding after splenectomy.

ITP is usually chronic in *adults*. There is no clear age at which children should be treated in a manner more like adults.⁴¹ Although data suggest that adolescents are more likely than younger children to develop persistent or chronic disease, there have been no studies investigating a benefit to altered treatment in this age group or the age at which point this effect is likely to be most present. Therefore

the management of adolescents should follow the usual management for children. Children with no or mild bleeding are managed with observation alone regardless of platelet count.

In children and adolescents \leq 17 years of age, use of IVIG is based on risk of bleeding and not on platelet counts. Most children do not require therapy with IVIG.^{40,43} In emergency situations, platelet transfusions given with IV corticosteroids and IVIG should be given for intracranial hemorrhaging or other life-threatening or serious bleeding.³³

Studies in children with ITP suggest the majority of children experience no bleeding or mild bleeding regardless of whether or not they initially receive drug therapy.⁴¹ ASH notes the decision to manage with observation requires a detailed discussion between the healthcare provider, patient and family. Treatment may be appropriate if follow-up cannot be assured, if there are other societal concerns (e.g., travel, distance from hospital), if there are concerns attributed to activity level or risk of bleeding, or there is a need for upcoming procedures associated with a risk of bleeding. For pediatric patients requiring treatment, a single dose of IVIG or a short course of corticosteroids are recommended as first-line treatment (long-term use of corticosteroids should be avoided). IVIG can be used if a more rapid rise in platelet count is desired.^{41,43}

ASH recommends pregnant patients requiring treatment for ITP receive either a corticosteroid or IVIG.⁴¹ Newborns of mothers with ITP are hospitalized.

In pregnant women, corticosteroids and IVIG are considered safe with regard to teratogenicity but may have maternal side effects including exacerbation of gestational diabetes and post-partum psychiatric disorders.⁴¹ The ASH guideline recommends IVIG or corticosteroids in pregnant patients requiring treatment with no recommendations for specific platelet counts at which patients should be treated. During labor and delivery, ITP management is based on assessment of maternal bleeding risks associated with delivery and epidural anesthesia, and the minimum platelet counts required to undergo these procedures.